A research-use guide to ipamorelin: how it engages the ghrelin receptor (GHS-R1a), why it is described as the first selective GH secretagogue, and an honest read of the animal and limited human data. RUO reference only.
The DAC modification is an elegant piece of chemistry that stretches a peptide’s half-life from minutes to a week. The human evidence behind it is one combined PK/PD trial from 2006. That asymmetry is the whole story.
GRF(1-29) is the rare growth-hormone peptide with a genuine regulatory past — approved, marketed as Geref, then withdrawn for commercial reasons. But its documented history is diagnosis and childhood deficiency, not the longevity claims now attached to it.
The decapeptide that orders GnRH neurons when to fire is among the best-mapped pieces of human reproductive physiology — and, candidly, still a research tool rather than a finished medicine.
A stabilised GHRH(1-44) analogue is the one growth-hormone secretagogue in this catalogue with a regulatory approval behind it. That approval is narrow, conditional, and routinely misread.
A clear, honest map of the growth-hormone-secretagogue class — the peptides studied to coax the pituitary into releasing more of its own hormone — and why their evidence base is thinner, and stranger, than the marketing suggests.
Enclomiphene is the purified trans-isomer of clomiphene, a SERM studied for raising a man’s own testosterone by lifting estrogen’s brake on the brain. It carries unusually strong human evidence for this catalogue, yet remains an investigational, research-use-only reference compound.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.